OSD
The world of OSD treatments is undergoing constant change, with pharma companies under ever-increasing pressure to develop oral drugs that aid with patient compliance and ease of dosage.
In our latest roundtable with On Drug Delivery, our science and technology officer Torkel Gren dives into the latest trends and innovations currently shaping the OSD space.
Some of his key insights include:
- Overcoming poor API solubility: To manage the complexities associated with poor solubility of APIs for oral dose drugs, pharma companies are increasingly outsourcing their end-to-end development processes to specialist partners.
- Advances in understanding and analysis of OSD forms: The use of in-silico prediction is becoming more prevalent, and is set to significantly improve development speed for projects with solubility challenges, increasing the chances of successful development.
- Small molecule remains strong: The rise of biologics does not mean that innovation in the small molecule arena has come to an end; we will continue to see demand for formulation development for new small molecules over the next decade
Explore more of the latest insights and innovations taking place across OSD development by reading the roundtable discussion in full.